Kobayashi, Mizuki
Fujiyama, Nobuhiro
Tanegashima, Tokiyoshi
Narita, Shintaro
Yamamoto, Yoshiaki
Fujimoto, Naohiro
Ueda, Shohei
Takeuchi, Ario
Numakura, Kazuyuki
Habuchi, Tomonori
Matsuyama, Hideyasu
Eto, Masatoshi
Shiota, Masaki http://orcid.org/0000-0002-3306-4858
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K06592, 19K18551)
Nakatomi Foundation
Article History
Received: 3 June 2021
Accepted: 4 August 2021
First Online: 11 August 2021
Declarations
:
: Shintaro Narita received honoraria from Janssen Pharmaceutical, Bayer Yakuhin, AstraZeneca, Takeda Pharmaceutical, Sanofi, and Astellas Pharma. Tomonori Habuchi received honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, AstraZeneca, Sanofi, and Bayer Yakuhin, and research funding support from Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Sanofi, and Bayer Yakuhin. Masatoshi Eto received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, and Merck Biopharma, and research funding support from Sanofi, Bayer Yakuhin, Astellas Pharma., Ono Pharmaceutical., and Takeda Pharmaceutical. Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma, and research funding support from Daiichi Sankyo.
: The study was conducted under review board at Kyushu University (727-01).
: Written informed consent was obtained from all patients.